IMNN
**** Disseminated on Behalf of Imunon, Inc
What if your body’s immune system could be taught to fight cancer at the tumor site?
What if your immune system created a vaccine response that protected against infectious diseases without needing a virus or device to deliver it?
Recent data helped earn FDA Fast Track and Orphan Drug status (US and EU) and is now being tested in OVATION-3, a 500-patient Phase 3 registrational trial with overall survival as the primary endpoint
IMNN Has Less Than 4M in the Float According to Finviz
Hello Everyone,
We have another company that is brand new to our members we want you to research for today's session. This one has an excitingly low float of under 4 Million shares according to Finviz.
This is not a catalyst to be overlooked. We all know what can happen when these low float Nasdaq listed companies if momentum kicks in.
The merits of the company itself are encouraging as well. We have looked at hundreds of Biotechs over the past 10 years. It is rare to find one that has an active Phase III trial. The results of the studies thus far have been what the company is looking for and the numbers have been in the companies favor as they move forward.
IMUNON (Nasdaq: IMNN) is a clinical-stage biotech tackling one of oncology's more stagnant corners: frontline treatment for advanced ovarian cancer, a standard of care that hasn't meaningfully changed in 30-plus years and where no immunotherapy has ever shown a strong survival benefit.
Its approach is TheraPlas®, a non-viral DNA plasmid platform that delivers therapeutic genes straight into tumors. The lead candidate, IMNN-001, encodes IL-12 and is injected directly into the abdominal cavity to turn an immunologically "cold" tumor "hot." In a randomized Phase 2 trial (OVATION-2), it produced a 14.7-month median overall survival improvement over chemo alone — jumping to 24.2 months in patients also on PARP inhibitor maintenance. That data helped earn FDA Fast Track and Orphan Drug status (US and EU) and is now being tested in OVATION-3, a 500-patient Phase 3 registrational trial with overall survival as the primary endpoint. Dosing began Q3 2025, with full enrollment targeted for roughly Q1 2029.
New preliminary data, from a minimal residual disease (MRD) sub-study of that same Phase 2 program run with MD Anderson and Break Through Cancer, adds another encouraging signal: a lower MRD-positive rate with IMNN-001 (44% vs. 67% control), higher ctDNA clearance (87.5% vs. 62.5%), and a 100% no-evidence-of-disease rate at second-look surgery vs. 56% in control — alongside a clean safety profile, with no cytokine release syndrome or serious immune-related adverse events reported. The catch: this is a tiny readout, just nine patients per arm at the primary endpoint, not statistically powered, and explicitly described as preliminary and directional. The PARP inhibitor subgroup finding is similarly hypothesis-generating rather than randomized. Still, it echoes the OVATION-2 survival signal and adds another data point supporting the bet now riding on OVATION-3 — the trial that will actually determine whether this benefit holds up at scale.
What if your body’s immune system could be taught to fight cancer at the tumor site?
What if your immune system created a vaccine response that protected against infectious diseases without needing a virus or device to deliver it?
Most of us know DNA as the building block of life. It codes for everything, for all the proteins in our bodies.
At Imunon, they are pioneering the use of DNA as a therapeutic that codes for proteins which our body then uses to produce medicine where you need it, for as long as you need it.
The IMUNON team is pioneering technologies that provide the foundation for a range of therapeutics for common, difficult-to-treat forms of cancer as well as technologies for the development of DNA vaccines against infectious diseases.
TheraPlas™
TheraPlas™ is a novel, nonviral delivery system for the development of immunotherapies and other anti-cancer nucleic acid-based therapies.
They are bringing it to market focused on aggressive, hard to treat cancers, starting with advanced ovarian cancer.
There are 300,000 new diagnoses of Epithelial ovarian cancer (EOC) per year globally, 20,000 patients in the US alone, with 70% of diagnoses occurring in the late stage and a high recurrence rate.
Their IMNN-001 product is built on the TheraPlas™ platform, and targets the micro-environement of ovarian cancer via local production of safe and durable levels of a powerful anti-cancer immune agent, IL-12.
PlaCCine
PlaCCine is a novel platform for the development of nucleic acid vaccines for infectious diseases and cancer that leverages a multivalent approach and non-viral DNA technology to generate a robust humoral immune response as well as a robust and durable T-cell response.
More than 80 pathogenic viruses have been discovered since 1980, but less than 4% have a vaccine commercially available.
That’s where the PlaCCine platform comes in…
Their team is developing an array of prophylactic vaccines, with strong evidence of immunogenicity and durability of protection.
NEWS
Jun 23, 2026
IMUNON to Present at the Life Sciences Investor Forum on June 25th
Jun 22, 2026
IMUNON Announces Up to $10 Million Cash Financing
Jun 4, 2026
IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
May 5, 2026
Mar 31, 2026
Mar 25, 2026
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
Mar 24, 2026
IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY
Feb 5, 2026
Dec 30, 2025
MANAGEMENT
Stacy R. Lindborg, Ph.D.
President, Chief Executive Officer & Board Director
Stacy R. Lindborg, PhD, was appointed President and Chief Executive Officer of Imunon in May 2024. Dr. Lindborg has served on Imunon’s Board of Directors since June 2021. Dr. Lindborg has nearly 30 years of pharmaceutical and biotech industry experience with a particular focus on R&D, regulatory affairs, executive management and strategy development. She has designed, hired and led global teams, guiding long-term vision for growth through analytics and stimulating innovative development platforms to increase productivity. Prior to joining Imunon, Dr. Lindborg was Executive Vice President and Co-Chief Executive Officer at BrainStorm Cell Therapeutics where she will remain a member of the company’s Board of Directors. At BrainStorm she was accountable for creating and executing clinical development strategies through registration and launch and progressed its novel cell therapy for ALS through a positive Phase 3 Special Protocol Assessment (SPA) study with the U.S. Food and Drug Administration. She interacted frequently with investors and analysts, represented the company in the scientific community as well as with the media, and played an active role in discussions with potential business partners.
Douglas V. Faller, MD, PhD
Chief Medical Officer
Dr. Faller, an internationally recognized oncologist/hematologist and scientist, has nearly 30 years of pharmaceutical and biotech industry experience with a particular focus on clinical R&D, discovery, regulatory affairs, and strategy development. He has worked with small molecules, gene therapies, biologics and cell therapies to address a range of malignant and non-malignant diseases and disorders, including rare and genetic diseases, and neurological and neuropsychiatric disorders. He has extensive experience in early-stage development as well as global late-stage development and world-wide marketing approvals. He has taken molecules (including those discovered in his own academic laboratories) from first-in-human studies in the clinic, through registrational trials, international regulatory approvals and commercial launch. Prior to his position with the Company, Dr. Faller served as Chief Medical Officer of Skyhawk Therapeutics beginning in 2024, where he led the development of splicing modulators for the treatment of oncological and neurological disorders. From 2022 through 2024, he served as Chief Medical Officer of Oryzon Genomics, leading the development of epigenetic-modifying small molecules in oncology and neuropsychiatric disorders, and prior to that role, from 2015 through 2022, Dr. Faller was Executive Medical Director at Takeda Pharmaceuticals, where he led multiple programs in hematologic oncology, solid tumor malignancies and rare diseases, from first-in-human to global registrational trials and post-marketing trials. He was also extensively involved in Business Development for oncology, hematology and rare diseases. Dr. Faller was the scientific founder and CMO/CSO of Viracta Therapeutics, which he joined in 2019 and remained through 2021, after it became publicly traded and launched a pivotal trial of his therapeutic. Dr. Faller is the scientific founder or co-founder of four biopharma companies. Prior to working full-time in the biopharmaceutical industry, Dr. Faller was a professor at Harvard Medical School, and an attending physician at Brigham and Women’s Hospital, Boston Children’s Hospital and Dana-Farber Cancer Institute. He founded and directed the Comprehensive Cancer Center at Boston University, where he also served as the first Grunebaum Professor for Cancer Research, Vice-Chairman of the Department of Medicine, and Professor of Medicine, Biochemistry, Pediatrics, Microbiology, Pathology and Laboratory Medicine. Dr. Faller received a B.S. in biochemistry from the Massachusetts Institute of Technology, an MD from Harvard Medical School, and a PhD from the Massachusetts Institute of Technology in cancer molecular biology. He has authored more than 300 abstracts, 230 presentations and 375 manuscripts that have been published in peer-reviewed journals. He is certified in Internal Medicine, Hematology and Oncology, and is a Fellow of the American College of Physicians.
Josh Blacher
interim chief financial officer
Mr. Blacher currently serves as Interim Chief Financial Officer of Imunon, Inc. He has been an employee of Danforth Advisors since September 2022, where he has served as interim chief financial officer in a consulting capacity for numerous public life sciences companies. Prior to joining Danforth Advisors, Mr. Blacher served as Chief Business Officer at InMed Pharmaceuticals (Nasdaq: INM) from April 2018 to August 2019, as Chief Financial Officer of Therapix Biosciences (Nasdaq: TRPX) from April 2017 to April 2018, and as Chief Financial Officer at Galmed Pharmaceuticals (Nasdaq: GLMD) from October 2014 to March 2017. Earlier in his career, Mr. Blacher held senior positions at Teva Pharmaceuticals, Deutsche Asset Management, and Morgan Stanley. Mr. Blacher holds a Bachelor of Arts in Economics from Yeshiva University and a Master of Business Administration in Finance from Columbia Business School.
Kristin Longobardi, MBA
Senior Vice President, strategic operations
Kristin Longobardi was appointed Sr. Vice President, Strategic Operations for Imunon in October of 2024. She comes to Imunon with over 25 years of pharmaceutical and biotech experience driving process optimization and efficiency, portfolio management, financial planning and analytics, and operational strategy development. Prior to Imunon, Ms. Longobardi held a variety of leadership positions at Biogen for over 20 years, most recently, Vice President, Quality Operations and Performance responsible for driving global R&D quality and compliance, operational productivity, alliance management, and executional efficiencies. Prior to that, she was a Sr. Director of Business and Financial Operations first for Biogen Clinical Operations and then for all of R&D, spanning from 2009 to 2016. Before then, she was in Corporate Finance at Biogen. Ms. Longobardi began her career as a scientist at Genome Therapeutics working on DNA sequencing and analysis for the Human Genome Project and other microbial pathogens for drug development and diagnostics. Ms. Longobardi received a Bachelor of Science from Bucknell University and an MBA from Babson College.
Sincerely,
